Article Title: An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
Authors: Bardhan, M., Dey, D., Suresh, V., Javid, B., Venur, V., Joe, N., Kalidindi, R., Ozair, A., Khan, M., Mahtani, R., Lo, S.S., Odia, Y., & Ahluwalia, M.M
Journal: Expert Review of Neurotherapeutics
DOI: http://dx.doi.org/ 10.1080/14737175.2023.2293223
The declaration of interest section was initially published without R Mahtani disclosures.
It has now been updated with the following sentence in the original version.
Declaration of interest
MS Ahluwalia has received grants from Seagen and has consulted for Bayer, Novocure, Kiyatec, Insightec, GlaxoSmithKline, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem therapeutics, and GT Medical Technologies. M. S. Ahluwalia is also on Scientific Advisory Boards for Cairn Therapeutics, Pyramid Biosciences, Modifi Biosciences, and Bugworks and is a stock/shareholder with Mimivax, Cytodyn, MedInnovate Advisors LLC, and Trisalus Life Sciences. R Mahtani serves as a consultant/advisor for AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Gilead Sciences, Hologic, Eli Lilly and Company, Merck and Co, Novartis, Pfizer, Puma, Sanofi, Seagen Inc, Sermonix and Stemline. All other authors have no relevant conflicts of interest to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.